Rheumatology Advance Access originally published online on July 31, 2007
Rheumatology 2007 46(9):1506-1508; doi:10.1093/rheumatology/kem184
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2007. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Familiar association of Gitelman's syndrome and calcium pyrophosphate dihydrate crystal deposition disease—a case report
Department of Clinical and Experimental Medicine, Rheumatology Section, University Hospital GB Rossi of Verona P. Le LA Scuro 10, 1Division of Gastroenterology and 2Division of Internal Medicine C, Verona, Italy.
Correspondence to: A. Volpe, MD, Department of Clinical and Experimental Medicine, Rheumatology Section, University Hospital GB Rossi of Verona P. le LA Scuro 10, 37134, Verona, Italy. E-mail: reumatologia@sacrocuore.it
| The first 10% of the full text of this article appears below. |
SIR, Calcium pyrophosphate dihydrate (CPPD) crystal deposition disease (CDD) is characterized by the presence of CPPD crystals in the joint. There are two common clinical presentations of CPPD-CDD: pseudogout and chronic pyrophosphate arthropathy [1]. In the last decade, several cases of CPPD-CDD presenting with chondrocalcinosis and recurrent attacks of pseudogout in association with Gitelman's syndrome (GS) have been reported [2–4].
GS is an autosomal recessive renal tubular disorder resulting from loss-of-function mutations in the Na–Cl cotransporter (SLC12A3) gene,